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Abstract
Epigenetics encapsulates a group of molecular mechanisms including DNA methylation, histone modification and microRNAs
(miRNAs). Gestational diabetes (GDM) increases the risk of adverse perinatal outcomes and is associated with future offspring risk
of obesity and type 2 diabetes. It has been hypothesised that epigenetic mechanisms mediate an effect of GDM on offspring adiposity
and type 2 diabetes and this could provide a modifiable mechanism to reduce type 2 diabetes in the next generation. Evidence for this
hypothesis is lacking. Epigenetic epidemiology could also contribute to reducing type 2 diabetes by identifying biomarkers that
accurately predict risk of GDM and its associated future adverse outcomes. We reviewed published human studies that explored
associations between any of maternal GDM, type 2 diabetes, gestational fasting or post-load glucose and any epigenetic marker (DNA
methylation, histonemodification or miRNA). Of the 81 relevant studies we identified, most focused on the potential role of epigenetic
mechanisms in mediating intrauterine effects of GDM on offspring outcomes. Studies were small (median total number of participants
58;median number of GDMcases 27) andmost did not attempt replication. Themost common epigeneticmeasure analysedwasDNA
methylation. Most studies that aimed to explore epigenetic mediation examined associations of in utero exposure to GDM with
offspring cord or infant blood/placenta DNA methylation. Exploration of any causal effect, or effect on downstream offspring
outcomes, was lacking. There is a need for more robust methods to explore the role of epigenetic mechanisms as possible mediators
of effects of exposure to GDM on future risk of obesity and type 2 diabetes. Research to identify epigenetic biomarkers to improve
identification of women at risk of GDM and its associated adverse (maternal and offspring) outcomes is currently rare but could
contribute to future tools for accurate risk stratification.
Keywords Epidemiology . Epigenetics . Gestational diabetes .Mediation prediction . Pregnancy . Review
Abbreviations
GDM Gestational diabetes
miRNA microRNA
MR Mendelian randomisation
Hannah R. Elliott and Gemma C. Sharp contributed equally and are joint
first authors.
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00125-019-05011-8) contains peer-reviewed
but unedited supplementary material including a slideset of the figures
for download, which is available to authorised users.
* Hannah R. Elliott
hannah.elliott@bristol.ac.uk
* Deborah A. Lawlor
D.A.Lawlor@bristol.ac.uk
1 MRC Integrative Epidemiology Unit at the University of Bristol,
University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8
2BN, UK
2 Population Health Sciences, Bristol Medical School, University of
Bristol, Bristol, UK
3 Bristol Dental School, University of Bristol, Bristol, UK
4 Bristol NIHR Biomedical Research Centre, University of Bristol,
Bristol, UK
https://doi.org/10.1007/s00125-019-05011-8
/Published online: 17      October       2019
Diabetologia (2019) 62:2171–2178
Epigenetic epidemiology and its use
in gestational diabetes research
Epigenetics encapsulates a group of molecular mechanisms,
including DNA methylation, histone modification and
microRNAs (miRNAs), which can influence gene expression
and variation in both cellular and whole-organism phenotype.
An increasing number of clinical applications are emerging
that use data generated in the field of epigenetic epidemiology.
These include studies increasing our understanding of mech-
anistic pathways culminating in adverse health outcomes
across the life course [1] as well as the use of epigenetic
biomarkers as informative biomarkers in diagnosis, risk pre-
diction and prognosis [2, 3].
In this review we describe the potential of epigenetic re-
search: (1) to improve understanding of the causal paths be-
tween in utero exposure to gestational diabetes (GDM) or
pregnancy hyperglycaemia and offspring adiposity and type
2 diabetes (type 2 diabetes) risk; and (2) as biomarkers for
increasing the accuracy of predicting GDM risk and its asso-
ciated adverse (maternal and offspring) outcomes. We then
review and summarise current published human studies on
the epigenetic epidemiology of GDM with a focus on these
two areas of research.
Epigenetic mediation of in utero exposure to GDM on off-
spring health Normal pregnancy is associated with insulin
resistance, particularly from the second trimester, similar to
that found in type 2 diabetes [4–6]. These changes facilitate
transport of glucose across the placenta to ensure normal fetal
growth and development [4–6]. If maternal gestational insulin
resistance becomes too pronounced then maternal GDM may
be diagnosed. Traditionally, GDM has been defined as any
hyperglycaemia that is first identified during pregnancy, in-
cluding existing undiagnosed diabetes/hyperglycaemia.
Whilst early pregnancy tests are increasingly used to identify
and treat women with existing hyperglycaemia [7], this is not
universal and any impact of ‘GDM’ on epigenetic mecha-
nisms or adverse outcomes may be due to existing
hyperglycaemia or pregnancy-induced insulin resistance.
GDM is associated with adverse perinatal [6] and longer-
term offspring outcomes, including higher adiposity and ad-
verse cardiometabolic risk factors such as higher circulating
glucose and insulin [6, 8–10]. The latter may be due to devel-
opmental overnutrition and it has been hypothesised that epi-
genetic dysregulation is one mechanism underlying this asso-
ciation. However, other mechanisms could explain these as-
sociations, including shared familial socioeconomic, lifestyle
and genetic factors [11–13] (Fig. 1, pathways b and c).
Mediation is concerned with causal effects but it is com-
monly explored through conventional multivariable regres-
sion using the method suggested by Baron and Kenny more
than 30 years ago [14], without exploring the assumptions
specified by those authors [15]. The challenges of researching
causal molecular mediation, together with suggestions for
novel appropriate approaches, have recently been described
[15]. The path between maternal GDM and future offspring
type 2 diabetes risk could be mediated by multiple mecha-
nisms. For epigenetic mechanisms to mediate a hypothesised
developmental origins path between in utero exposure to
GDM and future offspring type 2 diabetes risk (Fig. 1,
pathway a), evidence for all three of the following causal
effects are required: (1) effect of GDM on future offspring
type 2 diabetes; (2) effect of GDM on some epigenetic mech-
anism in relevant tissues; and (3) effect of those epigenetic
mechanisms on future offspring type 2 diabetes.
Determining such causal effects requires robust replication
of associations and triangulation [16] of two or more different
methods with different sources of bias for assessing causality,
such as Mendelian randomisation (MR), [15], parental nega-
tive control studies [17], matched within-sibship designs [10]
and cross cohort comparisons [16]. Within-sibship analyses
provide some evidence for a causal effect of GDM on greater
offspring BMI [8, 10]. In epigenetic epidemiology, a paternal
negative control study found that most of the epigenome-wide
associations of maternal early pregnancy BMI with cord-
blood DNA methylation were similar to those of paternal
BMI, suggesting the maternal associations were unlikely to
be causal [17]. The extent to which such methods have been
used to explore epigenetic mediating mechanisms between in
utero exposure to GDM and offspring outcomes is one subject
of this review.
Given the systems and tissues potentially involved in this
hypothesised epigenetic mediating path, any research should
ideally explore epigenetic mechanisms in offspring blood (in-
cluding cord blood), placenta, pancreas, liver, muscle and ad-
ipose tissue. Access to blood and placental tissue should be
feasible as an increasing number of birth cohorts collect cord
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Fig. 1 Summary of pathways that produce an intergenerational associa-
tion between GDM and offspring type 2 diabetes (T2D). This figure is
available as part of a downloadable slideset
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blood or infant blood from screening blood spots, as well as
placental tissue [18–22]. However, taking fat, muscle, pancre-
as and liver biopsies is unlikely to be feasible and ethical
except in clinical cohorts where there is a clinical need. In
silico reference data, such as that available in resources like
the Genotype-Tissue Expression (GTEx) project [23], may be
valuable for information on differential epigenetic phenomena
in these tissues but those data are likely to come from small,
select and usually adult populations.
Epigenetics as biomarkers for diagnosis and risk prediction in
relation to GDMCurrent guidelines for screening and diagnos-
ing GDM vary between countries and institutions. Universal
OGTT of all pregnant women is rare and the benefit of doing
this is debated [7, 24, 25]. The practice of early pregnancy risk
factor screening to identify those at most risk of GDM (to
enable selection for a later diagnostic OGTT) does not appear
effective [24, 26, 27]. Other early pregnancy screening ap-
proaches, such as glucose challenge tests, HbA1c and random
or fasting glucose measurements, can be useful in identifying
women with undiagnosed type 2 diabetes [7] but do not seem
to be useful in identifying women with GDM or predicting
associated adverse outcomes [24, 28]. A definitive diagnosis
of GDM is made with an OGTT at around 26–28 weeks of
gestation. However, emerging evidence shows that fetal
growth trajectories already differ in those whose mothers are
subsequently diagnosed with GDM compared with those
whose mothers are not, from at least 12 weeks of gestation
[29, 30]. Thus, there is a need for biomarkers that are mea-
sured on samples collected in early pregnancy that accurately
predict GDM and its associated adverse perinatal and later
(offspring and maternal) outcomes. These could indicate
which women would benefit from early interventions (life-
style or pharmaceutical) to reduce risk, including future risk
of obesity and type 2 diabetes in mothers and offspring.
Unlike the use of epigenetic measures to explore me-
diation, their use as biomarkers does not require them to
be causally related to the outcome they are predicting
[31]. Causal methods and tissue specificity are therefore
not the focus in epigenetic biomarker research. What is
required is to show that epigenetic biomarkers that can be
readily assessed in blood or urine (which are routinely
collected at antenatal visits) improve the discrimination
and calibration of current risk prediction tools. It is also
important that prediction tools developed in one study are
validated in independent studies.
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Fig. 2 An overview of the PubMed search strategy to identify studies of interest. This figure is available as part of a downloadable slideset
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A review of current published literature
We searched PubMed for any pregnancy-related studies that
explored associations between any of maternal GDM, type 2
diabetes, gestational fasting or post-load glucose and any epi-
genetic marker (DNA methylation, histone modification or
miRNA) (Fig. 2). We did not restrict our search solely to
studies of GDM because of the varying methods that were
likely to have been used to diagnose GDM in different studies
and because existing hyperglycaemia or pregnancy-related in-
sulin resistance may have influenced both short-term and
long-term outcomes. We included any study, whatever its
aim and whether it hypothesised epigenetic variation that pre-
ceded the diabetes-related outcomes or vice versa. Cross-sec-
tional, case–control or cohort designs and global, epigenome-
wide and candidate gene studies were all included. We re-
stricted studies to those conducted in humans and written in
English. We extracted key data from each study with the aim
that this would provide important information on what is cur-
rently available in the published literature and how these stud-
ies might contribute to the two different potential uses of epi-
genetic epidemiology in GDM. We did not extract results or
assess risk of bias in each study as this was considered beyond
the scope of this paper. Similarly, we did not attempt to syn-
thesise or pool results from different studies. We do, however,
provide references from all studies and the data we extracted
from them in electronic supplementary material (ESM)
Table 2 (summarised in Fig. 3).
There were two main themes of research effort identified
from our literature search: (1) studies of associations of GDM
with offspring and/or placenta epigenetics (n = 55 studies),
which were primarily concerned with epigenetic mediation
of in utero exposure to hyperglycaemia on offspring subse-
quent health; and (2) studies of maternal epigenetics (n = 23
studies), which were mostly concerned with the role of epige-
netics in the aetiology of GDM or its progression to type 2
diabetes. Three articles spanned both of these themes, so the
total numbers of studies contributing to offspring/placenta and
maternal epigenetics were 58 and 26, respectively, and the
denominator used whenwe consider study themes (rather than
individual papers) was 84 (Fig. 3).
Fifty-eight of the 84 studies (69%) explored associations of
GDM, glucose levels/response or pre-existing maternal diabe-
tes in pregnancy with offspring and/or placenta epigenetics
(Fig. 3a). The most commonly studied epigenetic mechanism
in these studies was DNA methylation (48/58; 83%). There
were ten studies of offspring miRNA and one study of his-
tones (Fig. 3a). There were 25 studies of offspring tissues (22
in blood, one in adipose, one in adipose and muscle, one in
skeletal muscle), 24 studies of placenta and nine studies of
both offspring blood and placenta (Fig. 3c). In most of these
studies, the hypothesis or background rationale was that epi-
genetic mechanisms mediate any effect of GDM/glucose traits
on offspring outcomes. However, these studies mainly pre-
sented associations of GDM (or a related exposure) with
offspring/placenta methylation and exploration of any causal
effect or effect on downstream offspring outcomes was lack-
ing. Five of the studies conducted mediation analysis. In one
study, two-step MR provided some evidence for differential
DNAmethylation levels near the leptin gene (LEP) mediating
the effect of maternal fasting glucose on neonatal leptin levels
[32]. This study was conducted in just 485 mother–offspring
pairs and both offspring DNA methylation and leptin were
measured in cord blood. In a study of 835 mother–offspring
pairs, evidence from structural equation modelling suggested
that GDMmediated an effect of obesity on fetal-side placental
DNA methylation of the LEP promotor region [33]. Three
further studies using the Baron and Kenny method reported
evidence that DNA methylation might mediate the following
effects: (1) the effect of in utero exposure to GDM on child-
hood cardiometabolic traits (specifically, differential methyla-
tion around VCAM-1 [also known as VCAM1]) [34]; (2) the
effect of maternal hyperglycaemia on offspring leptin levels at
birth [35]; and (3) the effect of gestational type 2 diabetes on
type 2 diabetes risk in offspring [36]. Of these five mediation
analyses, one attempted to replicate findings in an indepen-
dent study. Overall, just under half of the studies (27/58; 47%)
attempted replication of findings in an independent cohort or
conducted in vitro assays to support the main study findings,
although at least 12 of the 58 studies (21%) noted the need for
additional replication or validation (see ESM Table 2).
The second predominant theme of research effort was in
identifying associations between maternal epigenetics and
GDM or glucose levels/response in pregnancy (26/84 studies;
31%; Fig. 3a). Most of these studies aimed to explore the
aetiology of GDM and/or the progression to type 2 diabetes.
There were 20 studies of blood, two of the maternal side of the
placenta, two of maternal adipose tissue, one of omentum and
one of both blood and the maternal side of the placenta (Fig.
3c). Most studies of maternal epigenetics evaluated miRNA
expression (15/26; 58%; Fig. 3a). Four studies explored pre-
diction of GDM risk, using area under the receiver operating
curve (AUROC) to test predictive discrimination and two of
these four studies attempted to validate or replicate their find-
ings. However, it was unclear whether the miRNAs identified
from these studies were predictive of disease independently of
known (clinical) predictors, or were more accurate than these
known predictors, as these comparisons were not made.
Fig. 3 Summary of human epigenetic studies related to GDM or
hyperglycaemia in pregnancy. In (c) the size of the circles reflects the
number of studies in each tissue. The numbers of studies (given within
the circles) total 84 (rather than 81) because three studies contributed to
both of the broad areas and are depicted twice in this figure. In (d), for
case–control studies, the length of the vertical bar below the white
horizontal line shows the proportion of GDM cases, relative to the total
length of the bar. T1D, type 1 diabetes. This figure is available as part of a
downloadable slideset
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Overall, among the 26 studies that examined maternal epi-
genetics as causal risk factors for (or predictors of) GDM, only
ten (38%) attempted validation or replication of their results or
included in vitro assays to support the main study findings. At
least five of the 26 studies (19%) noted that additional repli-
cation or validation of study findings were needed (see ESM
Table 2).
Across both research themes, studies were split evenly be-
tween candidate-gene- and array-based approaches, with a
small proportion of studies assessing global or other measures
(Fig. 3b). Sample sizes were small (median n = 58, median n
cases = 27) and there was no obvious pattern of association
between sample size and studied epigenetic mechanism or
data type (Fig. 3d).
Discussion: conclusions and future research
Our review shows that there is a substantial body of
epigenetic epidemiology research in relation to GDM.
Most of this articulates an interest in the possible me-
diation by epigenetic phenomena of a possible causal
effect of maternal GDM on offspring future health in-
cluding future risk of obesity and type 2 diabetes.
Future research in this area should attempt to replicate
findings, expand the range of causal analysis approaches
applied to this question and, where possible, triangulate
across these to explore whether epigenetic mechanisms
that may be influenced by GDM relate to future adverse
offspring outcomes.
Seeking replication and exploring causality through
other methods such as negative control paternal studies
and MR require large samples sizes and necessitate col-
laboration across studies. Thus, endeavours such as the
Pregnancy And Childhood Epigenetics (PACE) consor-
tium [37] are important for taking this research forward.
Any study that has epigenome-wide data collected using
the Ilumina 450K or EPIC BeadChip and any pregnan-
cy, neonatal or childhood data can join PACE. There are
no restrictions on sample size, geography or ethnicity of
participants and members of the consortium can propose
and lead projects (https://www.niehs.nih.gov/research/
atniehs/labs/epi/pi/genetics/pace/index.cfm). To date, the
collaboration has largely looked at multivariable
observational association, although one study (of
maternal BMI) included a parental negative control
study [17].
MR is increasingly being adopted to strengthen caus-
al inference in epigenetic studies [38, 39]. The two-step
MR framework is relevant to the exploration of the
causal pathways linking GDM to offspring outcomes
via epigenetic mechanisms [15]. The feasibility of ap-
plying MR to address questions pertaining to the
potential long-term consequences of in utero exposures,
such as GDM, is improving due to the increasing avail-
ability of relevant genome-wide genetic data and the
development of relevant statistical methods [40–43].
However, it may not be feasible to use MR to deter-
mine a specific intrauterine effect of exposure to mater-
nal GDM on offspring type 2 diabetes given the over-
lapping pathophysiology and genetic correlates between
GDM and type 2 diabetes [15]. It may also not be
feasible to use MR if there are no strong genetic instru-
ments available for a particular epigenetic mark.
However, genome-wide association studies of DNA
methylation have been published [44, 45], with a
large-scale meta-analysis underway by the Genetics of
DNA Methylation Consortium (GoDMC). These efforts
are generating an extensive catalogue of SNPs that tag
methylation variation (meQTL) and these in turn can be
used in MR and have been applied in a systematic way
across many outcomes simultaneously [45].
Assessment of epigenetic measures for prediction of
GDM was rare among studies identified (n = 4). The abil-
ity of epigenetic marks to integrate genetic and non-
genetic factors in a biologically stable and technically
reproducible way means they have high potential as bio-
markers. Perhaps uniquely, epigenetic marks can ‘capture’
information on endogenous and exogenous exposures, in-
cluding risk factors and very early consequences of dis-
ease processes, thus promising to be an effective tool in
early detection and future prediction and prognosis. The
use of epigenetic biomarkers in this way is established in
cancer research [46], and this is an area of research that is
likely to see considerably more attention in other areas in
future years (including pregnancy complications, where
accurate risk prediction remains poor).
In conclusion, determining whether GDM causes (via
intrauterine mechanisms) increased risk of future offspring
type 2 diabetes is important, because if it does there could
be an intergenerational cycling or risk that would acceler-
ate the increasing risk of type 2 diabetes and GDM. If there
is a causal effect, epigenetic mechanisms could provide a
potential modifiable target for intervention development to
break this cycle. There is increasing optimism that epige-
netic information can be used as a biomarker to predict
future likelihood of adverse outcomes. As methods for
identifying risk of GDM early in pregnancy (before fetal
overgrowth begins) are lacking, this could be valuable for
identifying women who might benefit most from more-
intensive antenatal monitoring and interventions (lifestyle
or pharmaceutical) to optimise fetal growth and minimise
maternal hyperglycaemia. The assembled published evi-
dence suggests that this is a fruitful avenue of research to
explore. However, larger, more robust studies are required
to strengthen the current evidence base.
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